Androgen Receptor (ANDR) Antibody Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P10275 |
---|---|
Other Accession | Q5JUN9 |
Clone Names | 2110602 |
Gene ID | 367 |
---|---|
Other Names | Androgen receptor, Dihydrotestosterone receptor, Nuclear receptor subfamily 3 group C member 4, AR, DHTR, NR3C4 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP2509a is HPHARIKLENPLD, containing a predicted sumoylation site from the central region of human ANDR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | AR |
---|---|
Synonyms | DHTR, NR3C4 |
Function | Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues (PubMed:19022849). Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. |
Cellular Location | Nucleus. Cytoplasm Note=Detected at the promoter of target genes (PubMed:25091737) Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1. |
Tissue Location | [Isoform 2]: Mainly expressed in heart and skeletal muscle. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Androgen receptor (ANDR) has 3 major functional domains: the N-terminal domain, DNA-binding domain, and an androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. The gene for this protein contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of the protein. Expansion of the polyglutamine tract causes spinal bulbar muscular atrophy (Kennedy disease). Mutations are also associated with complete androgen insensitivity (CAIS). PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor; sumoylation of ANDR represses androgen receptor dependent transcription.
References
Nishida, et al. J. Biol. Chem. 277 (44), 41311-41317 (2002)Sills, E.S., et al., Int. J. Mol. Med. 9(1):45-48 (2002).Chavez, B., et al., J. Hum. Genet. 46(10):560-565 (2001).Ahmed, S.F., et al., J. Clin. Endocrinol. Metab. 85(2):658-665 (2000).Marcelli, M., et al., Cancer Res. 60(4):944-949 (2000).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.